<DOC>
	<DOCNO>NCT02372916</DOCNO>
	<brief_summary>Given age population affect wet AMD lack effective GA treatment , crucial ass safety profile repeat ranibizumab injection AMD patient GA , particularly possible risk GA development enlargement . This potential adverse effect significant implication discussion patient regard risk benefit AMD treatment injection frequency . While monthly injection provide slight improvement visual acuity 2 year ( Martin et al. , 2012 ) , risk GA enlargement may offset benefit visual acuity . Previous study assess association intravitreal ranibizumab injection de novo GA development injection-naïve eye ( Martin et al , 2012 , Querques et al. , 2012. , Grunwald et al. , 2014 ) , rather GA enlargement patient preexist GA. To best investigator knowledge , prospective study assess association intravitreal ranibizumab injection rate GA progression patient pre-existing GA . There also prospective study compare morphological feature GA patient receive intravitreal injection , concordance GA enlargement rate 2 eye among patient receive receive treatment .</brief_summary>
	<brief_title>Geographic Atrophy Intravitreal Ranibizumab Injections</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age &gt; 50 year old Patients preexist GA secondary AMD NOT require intravitreal injection ( i.e . Dry AMD ) Patients preexist GA CNV secondary AMD require intravitreal injection ( i.e . Exudative AMD ) treatmentnaïve patient Patients preexist GA CNV secondary AMD require intravitreal injection ( i.e . Exudative AMD ) receive previous intravitreal injection . Able maintain steady fixation foveal parafoveal area fundus image Geographic atrophy ( GA ) , fovealsparing foveal GA. Fovealsparing GA define GA within 250μm centre ( Sunness et al . 1999 ) Area GA image entirety contiguous area peripapillary atrophy Adequate medium clarity quality fundus image Inability undergo study procedure ( e.g . contraindication intravitreal injection ) attend followup visit CNV attributable cause AMD Active intraocular inflammation Any retinopathy , include diabetic retinopathy , retinal venous occlusion , epiretinal membrane</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>